Thef irsts tepo fc oagulation factor XIII (FXIII) activation involves cleavage of theF XIIIa ctivation peptide (FXIII-AP)b y thrombin. However, it is not knownwhether the FXIII-AP is released into plasma upon cleavage or remains attached to activated FXIII.Theaim of the presentwork was to study thestructureo ff reeF XIII-AP,d evelop an assay forF XIII-AP determination in human plasma, andtoanswerthe question whether FXIII-AP is released into plasma.Weusedab-initio modeling and moleculard ynamics simulations to study thes tructureo ff ree FXIII-AP.W er aisedm onoclonal and polyclonal antibodies against FXIII-AP and developed ah ighlys ensitive and specific
Introduction
Activatedb lood coagulation factor XIIIa( FXIIIa), whichi sa transglutaminase,covalently cross-links fibrin polymersand incorporates antifibrinolytic proteins into fibrin. In consequence of these reactions,the fibrin clot obtains sufficient stability and resistancet op remature fibrinolysis (1, 2) . According to these functions in clot formation, FXIII is amajor player in anythrombo-embolice vent, namely myocardiali nfarction, ischemic stroke, deepveinthrombosis, and pulmonaryembolism (3) (4) (5) (6) .
FXIII zymogen circulates in plasma as atetramer of twocatalytic A-subunits and twoc arrier B-subunits (A 2 B 2 ). In plasma, thrombin initiatesthe physiological conversion of the FXIII zymogeninto the active enzyme by cleavage of the N-terminal activation peptide (AP), resulting in FXIII A' 2 B 2 .This reaction is greatly enhanced by fibrin. Then, the dissociation of the A' -and B-subunits is inducedb yc onformational changes due to the binding of Ca 2+ ,again enhanced by fibrin. Finally, in the absence of the B-subunits and in presence of Ca 2+ ,t he A' -subunits assume their active configuration (A*) (7) .
Despite theincreasing interest in FXIII,its numerousfunctions,and its role in variousdiseases,several issues, in particular regarding FXIII activation, have not beenresolvedyet.Itisnot known whether the AP cleavedfrom plasmaticFXIII is actually released or remains associated with the activatedprotein in vivo. In the 1970s, Schwartzetal. (8) showed the electrophoretic pat-ternso fn on-activateda nd activatedF XIII on polyacrylamide gels in sodium dodecyl sulfate. When activatedbythrombin, the A-subunit decreasesinmolecular weight by 4,000, indicating releaseo ft he AP.F rom the first three-dimensionals tructureo f FXIII obtainedfrom X-raycrystallographyYee et al. (9) deduced that the AP blocks the access to the active site cavity,and thereforeimportant conformationalchangesincluding removalorat leastm ovement of the AP are required forF XIII activation. Later, however, X-rayc rystallographyo ft he FXIII A' 2 dimer after cleavage of the AP by thrombin gave some evidencethat the AP is not released,sincenosignificant conformationalchanges in the protein were found,and the AP had almost the same conformation and occupied the same position as within the zymogen structure (10) . On the conformation of the free AP itself,ifreleased,nothing is known so far. Someevidencefor the release of FXIII-APafter its cleavage comesfrom in-vitroexperiments studying the kinetics of FXIII activation in purifiedsystems, where free AP wasd etected by high-pressure liquidc hromatography (HPLC) (11, 12) . Another study has describedmassspectrometric detection of the AP after extensive processing of serum samples (13).H owever,a ll experimental settings mentioned above involved special,n on-physiological conditions,e .g. denaturating agents, high concentrations for crystallization, protein precipitation, chemical solvents, or high pressure.T herefore, these resultsmay not applytothe situation in vivo .Insummary, there exist no data whether or notthe FXIII-APisreleased under physiological conditions into plasma uponF XIII activation.
In the work we present here, we used ab-initio modeling and moleculard ynamics simulations to study the structureo ff ree FXIII-AP and compared its putative structure to FXIII-AP bound to the parent FXIIIprotein in ordertoinvestigatethe theoretical feasibility of raising specific antibodies against FXIII-AP.Wethen produced specific antibodies against FXIII-APand developedasensitive and specificELISA methodfor direct detection of circulating FXIII-AP. If the FXIII-AP is indeed released in vivo,this maybeofmajor clinical interest since it could serveasanewmarker foracutethrombotic disease.
Materials andmethods

Structural analysis
Structural analysis wasb ased on the crystals tructureo ft he FXIII A 2 -homodimer(14) obtained from the Protein Data Bank PDB (http://www.rcsb.org/pdb/; PDB Entry1 F13). Thea mino acids equence of the FXIII-AP (amino acids1 -37) wass ubmitted to the HMMSTR/Rosetta Prediction server( http:// www.bioinfo.rpi.edu/~bystrc/hmmstr/server.php). This server uses ab-initio methods(I-sites, HMMSTR, and Rosetta)todetermine the structureofthe backbone. Coordinates of the side chain atoms were added using the CHARMM version 31b1 software with the CHARMM19 forcefield and EEF1 implicit solvation model ( 15, 16) . The conformation generated ab initio by the HMMSTR/Rosetta server wasn ot interpreted as ap ossible structureofthe AP butwas used solely as astarting conformation for MD simulations.T wo other conformations were built using the same amino acidsequence of the FXIII-AP:afully extended structure and a"crystalstructure" by modeling the residues 1-4 and 37 whichare notdescribed in the FXIII A 2 -homodimercrystal structure.Using these threedifferent starting conformations, molecular dynamics( MD) simulations were performed to sample possible conformer(s)ofthe free AP.
First,aminimization of 5,000 steps usingsteepestdescend followedby500 steps of conjugate gradient wasperformed for allthreestructures.MDsimulations were carried outusing the implicit solvent forcefield EEF1/CHARMM19 parameters. The shake algorithm wasusedtorestrainthe hydrogen bonds and a time stepof2fswas used. Thesystem washeated from1Kto a final temperatureof300 Kincreasing the temperatureof0.5 K every6 ,000 steps. The MD simulations were thenp erformed further with atime stepof2fsat300 K.
Analysis of the secondarys tructurew as performed with STRIDE (17) . Figuresw ere produced with PyMOL( 18) and VMD (19).
Antibodyproduction
We developedantibodies against FXIII-APincollaboration with ABGENT Inc.( SanD iego, CA, USA). Thed etailedp rotocols can be accessedathttp://www.abgent.com. In brief, the AP was synthesizeda ccording to the publisheds equence (SETSRT AFGGRRAVPPNNSNAAEDDLPTVELQGVVPR, PDB Entry 1F13). After HPLC purification, the AP wasconjugatedtokeyhole limpet hemocyanin (KLH) as carrierp rotein.F or production of polyclonala ntibodies, twoN ew Zealand White rabbits were repeatedlyi mmunized,a nd several bleeds were takenb etween week 5a nd week 10 after the first immunization. Antibodyt iters were determinedb yE LISA against the AP.T he pooled bleeds were protein Gaffinity purifiedand affinity purified againstt he AP.F inally, we obtained 9m lo fp urified antibody solution (0.31 mg/mli np hosphate-buffereds aline)f rom onerabbit and 13 ml (0.49 mg/ml) from the otherrabbit. Both polyclonalantibodies were testedagainst the free AP in reducing SDS-PAGE followedbyWestern blotting. We labeled2mlofthe higher-concentrated polyclonala ntibody with biotinu sing the EZ-Link ® Sulfo-NHS-LC-Biotinylation Kit (Pierce,R ockford, IL, USA). Forp roduction of monoclonal antibodiesa gainst FXIII-AP,B alb/cm icew ere repeatedlyi mmunized. After six weeks,the spleencells from the mousewith the highestantibody titer were isolateda nd fusedw ith myelomac ells. Clonesw ere grownand tested by ELISA against FXIII-AP and FXIII protein.
Clonesthat were positive againstFXIII-AP and negative against FXIII protein were subcloned twice. Theclone with the highest reactivity againstF XIII-AP and thel owestr eactivity against FXIII protein wasselected forlarge-scaleproduction with subsequent protein Gaffinity purification. Finally, we obtained 9ml of purified monoclonal antibody (0.61 mg/mlinphosphate-bufferedsaline).
ELISA development
We developedas andwich-type ELISAu sing eithert wo polyclonalrabbit anti-FXIII-AP antibodies, one of thembiotinylated, or acombination of one polyclonaland the monoclonal antibody. We appliedt he following assayp rocedure: Ninety-six-well microtiterp lates( Maxisorp, Nunc, Roskilde,D enmark)w ere coated with 100 µl perw ello ft he first polyclonal rabbita nti-FXIII-APantibody (concentration 1µg/ml in coating buffer con-taining 50 mM sodium carbonate, pH 9.6). The plate wasincubatedatroom temperature(RT)onashaker for 1hour (h),followedbyo vernight incubation at 4°C. After five washing steps with200 µl of washing buffer (50mMTris-HCl, 150mMNaCl, 0.1%T ween-20,0.01% sodium azide, pH 7.5), we blocked the plate with 200 µl of blocking buffer (50mMTris-HCl, 150mM NaCl,1%bovine serumalbumine,0.01% sodium azide, pH 7.5) and incubated it at RT on as haker for 1h .After five washing steps, we diluted standards and plasma or serum samples appropriatelywith dilutionbuffer(50 mM Tris-HCl, 150 mM NaCl, 0.1%bovine serumalbumine,0.01% sodium azide, pH 7.5) and loaded100 µl in duplicate onto the plate. After 1hofincubation at RT on ashaker,wewashed the plate five times, loadedeither 100 µl of the biotinylatedpolyclonalrabbit anti-FXIII-AP antibody( 1µ g/ml in dilution buffer) or 100µ lo ft he monoclonal mouse anti-FXIII-AP antibody (1 µg/ml in dilution buffer) onto the plate,and incubated it again for 1h.After five washing steps, we loadede ither1 00 µl of streptavidine-alkaline-phosphatase conjugate (10 µg/ml in dilution buffer; Sigma,F luka Chemie GmbH, Buchs, Switzerland)or100 µl of goat anti-mouse IgG labelled with alkaline-phosphatase (1/1,000 in dilution buffer; Sigma,F luka Chemie GmbH) onto the plate and incubatedi t againfor 1h.After five washing steps, we developedthe plate with 100 µl of p-nitrophenylphosphate (1 mg/mlin1Mdietha-nolamine containing 0.5 mM MgCl 2 ,pH9.8; Sigma) and incubateditatRTonashaker.Westopped the color-developing reaction after exactly 10 minutes (min) with 100 µl of 4MNaOH and measured optical density (OD) valuesonamicroplate reader at 405nmwith areference filterat550 nm (Tecan SLTRainbow Reader with MagellanS oftwareV 1.11, Tecan Austria GmbH, Grödig, Austria).
We assessedspecificity and sensitivity of the novelELISA methodb ym easuring FXIII-AP dilutionsi nd ilution buffer, FXIII-deficient plasma (congenitalFXIII-deficient plasmawith <1.0% FXIII as assessed by ELISA, Milan Analytica,LaRoche, Switzerland), and normal pool plasma.The synthetic FXIII-AP wasd ilutedt of inalc oncentrations ranging from 1µ g/ml to 10 pg/ml (256 nM to 2.6 pM) in dilution buffer,inFXIII deficient plasma(whichwas diluted1/10 and 1/100),and in normal pool plasma (diluted 1/10 and 1/100). In each dilution series, we includedablank without FXIII-AP.From the resulting concentration versusODcurves, we deduced linear range and detection limit of the ELISA and defined the standard curve.
Determinationofinvitro generated AP
Bloodf rom healthyv olunteersw as drawni nto 5-ml tubes (Monovette ® ,S arstedt AG,S evelen, Switzerland)c ontaining 0.5 ml trisodium citrate solution (0.106 M) for plasma separation or clot activator beads forserum separation. We centrifugatedthe plasma tubes immediatelyat2,000 gfor 20 min and then separated the citrated plasma.Serum tubeswere allowedtostand for 30 min before centrifugation (2,000g,20min) to letcoagulation proceed.
Fori n-vitro generation of AP,w ea ctivatedc itrated plasma with thrombin (Sigma)and stopped the reaction after different timep oints with the thrombin inhibitor Phe-Pro-Arg-chloromethylketone "PPACK" (Bachem, Bubendorf, Switzerland). We performed the experiment in twoparallelseries,once with and once without the fibrin polymerization inhibiting peptide GlyPro-Arg-Pro-amide acetate (GPRP; Bachem).W emixed 100µl of citrated plasma with 50 µl of GPRP(5mg/ml in tris-buffered saline, TBS) or with 50 µl of TBS forthe series without GPRP. We activatedwith 50 µl of thrombin (10 U/ml in TBS) or added 50 µl of TBSfor the non-activatedcontrol. We stoppedthe reactions after 1, 2, 3, 4, 6, 8, and 10 min by addition of 50 µl of PPACK( 140 µg/ml). The clotted samples without GPRPw ere centrifugatedat2,000 gfor 10 min, and the supernatant wasseparated. Fort he AP ELISA, we diluted the activatedp lasma samples1/50 in dilutionbuffer.
After centrifugation of thes erum samples, one aliquoto f each serums amplew as immediately analyzed,t wo other aliquots were kept for 4hat4°C in the fridgeand at RT.Serum was diluted 1/50 in dilution buffer forthe AP ELISA whichwas performedusing eitherthe twopolyclonals or the polyclonal/monoclonalcombination.
In all plasmaand serumsamples,w ealsodeterminedFXIII A-subunit antigen levels by an in-houseE LISA (20) . FXIII A-subunit antigen levels are expressedaspercentageofthe WHO 1 st InternationalStandard FactorXIII Plasma (NationalInstitute for Biological Standards andControl, NIBSC, Potters Bar, UK).
Analysis of plasma clots fortrappedAP
We generated plasma clots by incubating normalcitrated plasma with thrombin (finalconcentration 1.2 U/ml) and calcium chloride (finalconcentration 16 mM) for 2hat37°C.Wewashed the clotst hreet imesw ith 0.9%s aline and thena dded Laemmli sample buffer containing 54 mg/ml dithiothreitol. Afterboiling for 5min at 95°C and incubation for 30 min, the clotswere dissolved and analyzed by SDS-PAGE and Westernblotting.Synthetic AP wasusedasapositivecontrol.
Antibodyspecificitytowards syntheticand natural AP
Forgeneration of natural AP,weusedapurified system containing purified plasma FXIII (67.5 nM), thrombin (7.5 U/ml), calciumchloride (15 mM), and fibrinogen (6 mg/ml) (cofactor in FXIII activation).After incubation during 10 min at 37°C, the sampleswere centrifuged and the supernatant wasmeasured by ELISA. Acontrol sample without thrombin and calciumchloride and solutions of synthetic AP (67.5 nM and 135 nM) were analyzed by ELISA as well. Theconcentration of 135 nM AP corresponds to the releaseoftwo APsper FXIII tetramer,67.5 nM correponds to the release of onlyone AP per FXIII tetramer.The ELISA wasperformed eitherwith twopolyclonals, one of them biotinylated, or with the polyclonal-monoclonalc ombination. We also analyzed differentc oncentrations of synthetic AP and natural AP,derivedinthe above purified system, by SDS-PAGE and Westernblotting.
Results
Structural analysis
Figures1Aand Bshowthe conformation of the AP bound to the FXIII A 2 homodimer.Inthis structure, the amino acids 28-32 are involved in a β -strand,but no further regular element of secondarystructureisobserved. To investigatethe conformation of the free AP,eight MD simulations were performed starting from the crystal structure, af ullye xtendedc onformation, or ac onformation predicted ab initio by the HMMSTR/Rosetta Prediction server (Table 1) .
Starting from the crystals tructure, the initialA Pc onformation wasrapidlylost and β -strandswere formed. In allMD simulations the conformation of the crystalstructurewas never sampled,and the final partofmost trajectories had ahigh root mean square deviation (RMSD) from the homodimeric conformation and ah igher β -strand content (Table 1) ,s uggesting that the free AP does not assume the same structurea st he AP within the FXIII A 2 homodimer.MDsimulations starting from extendedorabinitiomodeledAPshowedalso ahigh tendencyto form β -strands (Fig. 1C) . At the end of the MD simulations, i.e. after 200 to 400 ns, all butone conformations had β -strands. In addition, some of the runs converged to the same β -strandsstructure. Figure 2summarizes the averagesecondarystructurecontent for each amino acid over allMDsimulations.
The N-terminal amino acids 5to14inthe free AP showeda higher tendencytoform β -strandsthan in the AP bound to nonactivatedF XIII. At thee nd of the MD simulations, six out of (10) .One monomerisrepresented in coloredribbons, theother is represented as asurface.The AP is colored in pink withthe N-terminus marked as aball (noticethat theaminoacids1-4 and 37-38 arenot displayedastheydonot have coordinates attributed in thecrystal structure [10] ). B) Structure of theAPasitisbound to theFXIII A 2 homodimer, takenfrom thecrystal structure. TheN-terminus is marked as ablue ball, the C-terminus as ared ball, the β -strand is coloredinyellow, turns/ bends arecolored in light blue.C)Putativestructure of free AP.The resultfromMDsimulationrun 8isshown as arepresentativepicture.The N-terminus is marked as ablue ball, theC-terminus as a redball, β -strands arecolored in yellow, turns/bends arecolored in light blue.
and purified. TheW estern blot shown in Figure 3A confirmed the binding betweenthe AP and polyclonalantibodies. We then developeda nE LISA methodw hich is basedo nt he sandwich principle, using either twopolyclonalantibodies or apolyclonal/ monoclonal combination. The ELISA functions over ab road rangeofFXIII-AP concentrationand is highlysensitive detecting AP concentrations as lowas0.01 ng/ml (2.6 pM). Figure 3A shows the AP concentration versusODcurvesofthe ELISA over arangeof0.01-100 ng/ml (2.6 pM -25.6 nM) of AP diluted in dilution buffer,FXIII-deficient plasma, and normal poolplasma. The detection limitofthe ELISA was0.01 ng/ml (2.6 pM) in dilution buffer and 0.1ng/ml (26 pM) in plasma (diluted at least 1/10). Furthermore,the ELISA is highlyspecific since dilution of AP in FXIII-deficient plasma and normal pool plasma gave similar curvestoAPdilutedinbuffer, indicating thatthe antigen/ antibody reaction is independent of the presenceofotherplasma components, includingplasma FXIII. We were able to detect differentAPconcentrations in FXIII-deficient plasma and normal pool plasma as accuratelyasindilution buffer.Blank valuesof the dilutedplasmaswere similar to the dilution buffer blank and gave no significant OD signals. Therefore,thereisnocross-reactivity with tetramericplasma FXIII. We finallydefinedrepresentative standard curvesofthe ELISA, shown in Figure 3B ,inthe linear partofthe concentration versusODcurve.
DeterminationofAPgenerated in vitro
In non-activatedcitrated plasma samplesfrom fourhealthyvolunteers, we found FXIII A-subunit antigenlevelsof114-147% (expressed as percentage of the InternationalS tandard FXIII Plasma), butw ec ould not detect anyF XIII-AP.I nt he serum samples from the same individuals, we measured high AP levels of 86-145 ng/ml (22-37nM), as determinedb yboth the polyclonalELISA and also the polyclonal/monoclonal ELISA, and lowF XIII A-subunita ntigen levels of <1-4%. In the serum samples kept for 4hat4°C we still found 80% and in the samples kept at RT 65% of the original AP concentration. Figure 4s hows the timec ourse of FXIII-APa nd FXIII A-subunit antigen levels after activation in vitro of citrated plasma. Withoutaddition of the fibrin polymerization inhibiting peptide, we observedfastclot formation in the samples. This is re-894 eightstructures had β -strandsinthis partofthe free AP (Fig. 1C) . This simulation result is of noticeableinterest since these amino acids 5to14ofthe AP areinclose contact to the FXIII A 2 homodimer and mayb ei nvolved in binding to the FXIII A 2 homodimer.Byformation of β -strandsinthis partofthe AP,the free AP maybeprevented from binding to FXIII A 2 .
In summary,t he MD simulations indicatedt hat the conformation of free FXIII-APi sl ikelyt ob ed ifferent from the structureofthe AP within the FXIII A 2 homodimer.Therefore, generation of antibodies specific for the free AP maybefeasible and mayrepresent astrategytoexploit the structural diversity between free and boundAP.
ELISA development and characterization
Rabbits and micewere successfullyimmunized with FXIII-AP, and amonoclonaland polyclonalantibodies could be generated Ta ble1:Moleculardynamics simulations. Theroot mean squaredeviation(RMSD) of the C α -atomsofthe final snapshotwas calculated at theend of each run. The reference conformationiseitherthe crystalstructure or the structureobtainedbyab-initio modeling. Only thesegment 5-36istaken into account forthe RMSD calculationbecauseresidues 1-4 and 37 aredisordered and notpresent in the crystal structure(PDBID1F13).The β -structure content wasevaluatedfor thefinal snapshotof each simulation. In comparison,the β -structure content of theAPinthe homodimericstructure is about 13%. flectedbythe ELISA resultsshowing afastincrease in FXIII-AP and af astd ecreasei nF XIII A-subunit ( Fig. 4A) .I ns amples withoutc lot formation due to inhibition of fibrin polymerization, we found similarAPlevels, alessprominent decreasein FXIII A-subunit antigenl evels, and the changes occurred slightlyslower (Fig. 4B) . On the Westernblot of the solubilized plasma clotswecould not detect anyAP(data not shown). Antibodyspecificitytowards syntheticand natural AP In order to investigatewhetherthe antibodies might exhibit different specificities towards synthetic AP and natural AP generated by FXIII activation, we compared the ELISAsignals of the same concentrations of synthetic and natural AP.Inthe ELISA using twopolyclonalantibodies, we measured the followingOD values( mean of twor eplicates): Synthetic AP (135n M) OD 0.298,s ynthetic AP (67.5 nM) OD 0.184, natural AP (derivedfrom 67.5 nM FXIII) OD 0.105. In the supernatant of the activatedsamples,the FXIII A-subunit wasnolonger detectable. Thus,compared to the synthetic AP,w emeasured 57%natural AP if one AP is released per FXIII tetramer,and 35% natural AP if twoAPs are released per FXIII tetramer.These resultsare consistent with our results obtainedf rom activatedp lasma/serum samples and indicate that the specificity of the polyclonalantibodies towards the natural AP is onlyhalfofthe specificity towards the synthetic AP.
No.S tarting conformation
In the ELISAusing the polyclonal/monoclonalcombination, we measured the followingODvalues (mean of tworeplicates): Synthetic AP (135n M) OD 0.328,s ynthetic AP (67.5 nM) OD 0.252, natural AP (derivedfrom 67.5 nM FXIII) OD 0.207. Thus,compared to the synthetic AP,w emeasured 63%natural AP if twoAPs are released per FXIII tetramer,a nd even 82% natural AP if one AP is released per FXIII tetramer.These results mayindicate that the Mab has ahigherspecificity towards natural AP thant he Pabs, and that the Mab mayb eb ettert han the Pabs for detecting natural AP.
When we visuallyc ompared synthetic and natural AP on a WesternB lot (Fig. 5) we found thatb andso fs ynthetic AP showedah igheri ntensity than bands of natural AP in comparable concentrations. This result points again towards different specificitiesofthe antibodies towards synthetic and natural AP and supports the results obtainedbyELISA.
Discussion
Fort he first time,w es howt hat upon activation by thrombin FXIII-AP is released into plasma where it can be directly quantified by asensitive and specificELISA method.
In our experiments, we avoided using ap urified system to allowthe best in vivo-likeconditions, since the release of the activation peptide could depend on variousc ofactors whicha re only present in plasma. In addition, the use of plasma or serum avoids non-physiological reagentsinthe reaction mixture.
We compared the conformation of the AP bound to FXIII with the putative conformation of the free AP by using ab-initio modeling and MD simulation. Av erys imilari mplicit solvent MD simulation protocol in combination with the same force fieldemployedhere wasshown in previous works to reproduce the NMRs olution structureo fat hree-strandeda ntiparallel β -sheet peptide,irrespectiveofthe starting conformation used in the MD runs (21) .Moreover,the native structure of helicalpeptidesa nd β -hairpin were reproduced correctly ( 22, 23) . Therefore, the MD simulation method whichw as appliedh ere to sample the conformation space of the free FXIII-AP is to be consideredassuitable and valid. We observedconformational differences between the free AP showing two-stranded antiparallel β -sheet structures and the bound AP whichhas only one β -strand butnofurther secondarystructures.These resultswere obtained consistentlyf rom repeated MD simulations and fromd ifferent MD simulations usingd ifferent starting conformations.Therefore, we concludethat our resultsdescribing the structureofthe free AP arestrongly supported,but still remain to be confirmed by nuclear magnetic resonance(NMR)studies.
Thes tructural considerations led us to the assumption that the conformations of the twoF XIII-AP forms are different in vivo.W ec oncludedt hat it mayb ef easible to raisea ntibodies whichare specific for the free FXIII-AP,provided thatanimals develop an immune response to the AP.Indeed, we obtained one monoclonal and twopolyclonalantibodies against FXIII-APthat do not cross-reactwith the non-activatedFXIII moleculeinplasma,and this enabled us to develop the first immunologic assay for FXIII-AP detection.I nan exts tep, we intend to develop furtherm onoclonala ntibodies and to characterizet he antigen/ antibody reactions by epitope mapping.
As shown,our FXIII-APELISA is highlysensitive.The standardc urve wass et in av eryl ow rangeo fF XIII-AP concentrations.This should enableustodetect even lowest amountsof FXIII-AP circulating in vivo.I fm assive amountso fF XIII-AP were generated during acutethrombotic events, the samples can be diluted. Furthermore,our FXIII-APELISA is highlyspecific, since we observedn oc ross-reactivity with tetramericF XIII in plasma. Theoreticallyi tc ould be possible that after activation and subsequent removalofthe B-subunits anew epitope on the A-subunit is presented whicht hen cross-reacts with our antibody.However,this is rather unlikely, sinceafter FXIII activation and dissociation of the subunits, the FXIIIA-subunit is trapped inside the forming clot where the cross-linking reaction takes placea nd activatedF XIII (FXIIIa)r emains associatedw ith fibrin (24) .
We can nowanswerthe questions on the AP'sfateafter FXIII activation in plasma:B oth after plasma FXIII activation by thrombin and after contact activation of the coagulation cascade to gain serum, high FXIII-AP levels can be measured in plasma/ serum. At the same time,o nlyt races of the FXIII A-subunit antigencan be detected after activation. This is consistent with the observations thatactivatedFXIII tightly binds to fibrin, becomesi ncorporated into the clot and is removedf rom circulation, and therefore no or hardly anyFXIII remainsinthe serum (24) .When we prevented clot formation by addition of GPRP peptide,wefound almost the same levels ofAP,but therewas still some FXIIIA-subunit antigen detectable. Thesefindings demonstratet hat the FXIII-APi sr eleased into plasma/seruma nd does not remain attached to its parent protein. If that were the case, we would expectt of ind onlyt races of AP in clotted samples, with the AP sticking to activatedFXIII trapped within the fibrin network, buthigherAPlevelsinthe non-clotted GPRP samples. Furthermore,p olymerizedf ibrin is obviouslyn ot necessary for releaseofFXIII-AP,sincewemeasured FXIII-AP in the presence of the fibrin polymerization inhibitor GPRP.
The stoichiometryofFXIII activation and AP detection remains to be investigated moreclosely.Infullyactivatedserum we measured 22-37nMofFXIII-AP.Under the assumption that both APs per FXIII tetramer arereleased during FXIII activation, this correspondstoonlyapproximately25% of the normal FXIII A-subunit plasma concentration of 130-160 nM (25).However, apreviousstudy showedthat cleavage of only one AP per FXIII molecule would be sufficient forcomplete activation of platelet FXIII (26) . Thus,ifonlyone AP per FXIII molecule is released and this is also applicablefor tetrameric plasma FXIII,then our AP levels measured in serumand activatedplasma would correspond to approximately 50% of FXIII plasma concentration.
In ordertoinvestigateiflarge amountsofcleaved FXIII-AP might remaintrapped insidethe fibrin clot, we solubilizedplasma clotsand analyzed thembySDS-PAGEand Westernblotting. Since we found no AP insidethe clot, we abandoned this possibility.
Another explanation maybedue to the secondarystructureof the AP.Analysis of its putative secondarystructureshowedthat certainamino acids probably assume certain preferred secondarystructures (which putatively distinguishes the structureofthe free AP from the bound AP), butitalso showedthat other segments maybequite flexible. This flexibility maybeareasonwhy some epitopesofthe AP maynot always be exposed and available for antibodybinding.
Forquantitation we made the standard curve of our ELISA with synthetic AP,which also servedasimmunogeninantibody production. However, there maybedifferences between the synthetic AP and the natural AP generated in vitro or in vivo during FXIII activation. Suchdifferences mayinclude posttranslational modifications.Ithas been described thatthe N-terminal serine of the AP is acetylated, and thatasparagine 17 is apotential glycosylation site ( 24) . Because of such differences, our antibodies might recognize the synthetic AP better than the natural AP,leading to underestimation of the natural AP.Our experiments comparing antibody specificity revealed thatdifferences in specificity towards synthetic AP versusnatural AP mayindeedrepresent amajor explanation for the underestimation of FXIII-APin fully activateds erum.U sing am onoclonala ntibody we were able to detect even up to >80% of natural AP comparedtosynthetic AP.Therefore,the detection rate of natural AP cansurely be increased by furtheroptimisation of the antibodies, targeting at ahigherspecificity towards the natural AP.
Further reasonsfor the observeddiscrepancymay be incomplete FXIII activation, adsorption to otherplasma or serumproteins, or proteolytic degradation of the FXIII-AP.However,our experiments do provide sufficient evidencet hat as ignificant amount of FXIII-AP is released into plasma after activation of the zymogen, where it can be quantified.
Being reasonably stable over several hours,the FXIII-APfulfills one of the prerequisits of ad iagnostic marker and should therefore be measurable in fresh plasmasamples fordiagnosis of acutethrombotic events, similar to D-dimer testing.
We hypothesize that FXIII-APmay represent anovel marker in acutethrombotic events. This markermay be of major clinical importance, sinceitwould represent the final activation stepof the coagulation cascade, and it would be the first marker whichis generated exactly at the time of clot formation. In order to supporto ur hypothesis, clinicals tudiesa re required whichs hould address the question of clinicalr elevance as well as aspectso f kinetics and stability of the FXIII-APinplasma samples.
